Influenza A H7N9 virus therapies

Patent metadata

Field	Value
Publication number	US-9879066-B2
Application number	US-201615215738-A
Country	US
Kind code	B2
Filing date	Jul 21, 2016
Priority date	Jan 27, 2014
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

The present invention provides anti-influenza A virus antibodies effective at binding, neutralizing, and treating influenza A H7N9 virus, compositions comprising such antibodies, and methods of using the same.

First claim

What is claimed is:

1. A method for preventing or treating influenza A H7N9 virus infection, the method comprising administering to a subject having or at risk for having influenza A H7N9 virus infection a therapeutically effective amount of an antibody, wherein the antibody comprises three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3) and three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3),
wherein:
(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:56;
(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:57;
(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:58;
(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:59;
(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:60; and
(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:61.

2. The method of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:74.

3. The method of claim 1 , wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:75.

4. The method of claim 1 , wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:74, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:75.

5. The method of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:76.

6. The method of claim 1 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:77.

7. The method of claim 1 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:76, and the light chain comprises the amino acid sequence of SEQ ID NO:77.

8. A method for preventing or treating influenza A H7N9 virus infection, the method comprising administering to a subject having or at risk for having influenza A H7N9 virus infection a therapeutically effective amount of an antibody, wherein the antibody comprises three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3) and three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3),
wherein:
(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:62;
(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:63;
(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:64;
(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:65;
(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:66; and
(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:67.

9. The method of claim 8 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:78.

10. The method of claim 8 , wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:79.

11. The method of claim 8 , wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:78, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:79.

12. The method of claim 8 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:80.

13. The method of claim 8 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:81.

14. The method of claim 8 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:80, and the light chain comprises the amino acid sequence of SEQ ID NO:81.

15. The method of any one of claims 1 - 14 , wherein the method further comprises administering an additional therapeutic agent, wherein the additional therapeutic agent is a neuraminidase inhibitor, an anti-hemagglutinin antibody, or an anti-M2 antibody.

16. The method of claim 15 , wherein the neuraminidase inhibitor is oseltamivir, zanamivir, or peramivir.

Assignees

• Genentech Inc

Inventors

• Chai Ning
• Mcbride Jacqueline
• Swem Lee

Classifications

• A61K39/39575 Primary

  against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/567

  Framework region [FR] · CPC title